



Prescriber Signature: ____

ENTYVIO (VEDO				AND PRESCRIPTION	N SHE	ET.
Patient Information						
Patient Name:				Date:		
DOB:				Height:		☐ inches ☐ cm
Allergies:				Weight:		☐ lbs ☐ kg
Primary Diagnosis						
Diagnosis ICD-10 Diagnosis				ICD-10		
☐ Adult Ulcerative Colitis (UC)	K51.90	☐ Moderate t	Crohn's Disease		K50.01	
☐ Other:						
Medication Order						
Initial dose: Infuse 300mg IV over at least 30 min on Weeks 0,2 and 6 ☐ Maintenance Dose: Infuse 300mg IV over at least 30 min every 8 weeks ☐ Other						m date of nature unless icated below Refills ate. Initiate plan of
Ancillary Orders						
Pre-medications: ☐ Diphenhydramine: 25mg PO 30 min pre-infusion ☐ Acetaminophen: 650mg PO 30 min pre-infusion ☐ Famotidine: 20 mg PO x1 dose ☐ Other pre-meds: ☐ Refill x one year			IV Flush Orders: ☐ Peripheral: NS 1-3 mL before/after use ☐ Implanted VAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw. Heparin (100 unit/mL) 3 to 5 mL final flush ☐ CVAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw Heparin (10 units/mL) 3 to 5 mL final flush ☐ Refill x one year			
Anaphylaxis Protocol: Epinephrine Auto-Injector dual pack: Adult: 0.3mg Children: 0.15 mg Administer epinephrine IM in the event of anaphylaxis. May repeat x 1 as needed, Call 911. Refill x 1yr						
Therapy Specific Documentation			Other Required Documentation			
Please include the following lab results required for infusion. CDAI Index Score QuantiFERON-TB Gold Hep B Screening CMP, CBC and LFTs Other:			 □ Patient Demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise. □ H&P OR progress note(s) □ Medication List (include prior/failed DMARDS, biologics, or steroid use) 			
Provider Information						
Provider Name:				Provider Phone:		
Provider NPI:				Provider Fax:		
Provider Address:						
authorize KabaFusion and its representatives to act as an a for the patient listed above. I understand that I can revoke the					nd any futi	ure refills of the same prescription

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.